Study of Aspirin Metabolism and Metabolic Health Markers in Pregnant Women at Risk for Preeclampsia

What this Trial Is About

Researchers are studying the relationship between how aspirin is processed in the body and markers of metabolic dysfunction in pregnant individuals at risk for preeclampsia. The study focuses on understanding these connections during pregnancy, particularly in those recommended aspirin for preeclampsia prevention based on specific risk factors. Participants will undergo a single study visit between 14 and 20 weeks of gestation where they will ingest 75 grams of glucose. During this visit, various blood and urine samples will be collected to measure aspirin metabolites and metabolic markers. Additional assessments include indirect calorimetry, body composition measurements, surveys, and neonatal measurements. The study measures include glucose tolerance, salicylate levels, thromboxane levels, insulin resistance, and lipid profiles. Throughout the study visit, researchers will monitor metabolic responses and aspirin metabolism at specific time points after glucose ingestion. Participants are expected to fast before the visit and will be assessed for multiple metabolic and biochemical markers to evaluate their relationship with aspirin metabolism. The total participation involves a single visit with detailed sample collection and metabolic assessments, with safety and compliance monitored by the research team.

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia